Switch theme
Sign up to access all valuation multiples
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
1996
244
LTM Revenue $87.7M
LTM EBITDA $1.9M
$29.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Rockwell Medical has a last 12-month revenue (LTM) of $87.7M and a last 12-month EBITDA of $1.9M.
In the most recent fiscal year, Rockwell Medical achieved revenue of $101M and an EBITDA of $3.0M.
Rockwell Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Rockwell Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $87.7M | XXX | $101M | XXX | XXX | XXX |
| Gross Profit | $14.9M | XXX | $17.5M | XXX | XXX | XXX |
| Gross Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA | $1.9M | XXX | $3.0M | XXX | XXX | XXX |
| EBITDA Margin | 2% | XXX | 3% | XXX | XXX | XXX |
| EBIT | -$2.1M | XXX | $0.6M | XXX | XXX | XXX |
| EBIT Margin | -2% | XXX | 1% | XXX | XXX | XXX |
| Net Profit | -$3.1M | XXX | -$0.5M | XXX | XXX | XXX |
| Net Margin | -3% | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Rockwell Medical's stock price is $1.
Rockwell Medical has current market cap of $33.5M, and EV of $29.0M.
See Rockwell Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $29.0M | $33.5M | XXX | XXX | XXX | XXX | $-0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Rockwell Medical has market cap of $33.5M and EV of $29.0M.
Rockwell Medical's trades at 0.3x EV/Revenue multiple, and 9.8x EV/EBITDA.
Equity research analysts estimate Rockwell Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Rockwell Medical has a P/E ratio of -11.0x.
See valuation multiples for Rockwell Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $33.5M | XXX | $33.5M | XXX | XXX | XXX |
| EV (current) | $29.0M | XXX | $29.0M | XXX | XXX | XXX |
| EV/Revenue | 0.3x | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBITDA | 15.7x | XXX | 9.8x | XXX | XXX | XXX |
| EV/EBIT | -13.9x | XXX | 47.8x | XXX | XXX | XXX |
| EV/Gross Profit | 1.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -11.0x | XXX | -69.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 9.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRockwell Medical's last 12 month revenue growth is -19%
Rockwell Medical's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Rockwell Medical's rule of 40 is -24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Rockwell Medical's rule of X is -44% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Rockwell Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -19% | XXX | -14% | XXX | XXX | XXX |
| EBITDA Margin | 2% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Growth | -244% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -24% | XXX | -16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -44% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rockwell Medical acquired XXX companies to date.
Last acquisition by Rockwell Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Rockwell Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Rockwell Medical founded? | Rockwell Medical was founded in 1996. |
| Where is Rockwell Medical headquartered? | Rockwell Medical is headquartered in United States of America. |
| How many employees does Rockwell Medical have? | As of today, Rockwell Medical has 244 employees. |
| Who is the CEO of Rockwell Medical? | Rockwell Medical's CEO is Dr. Mark Strobeck, PhD. |
| Is Rockwell Medical publicy listed? | Yes, Rockwell Medical is a public company listed on NAS. |
| What is the stock symbol of Rockwell Medical? | Rockwell Medical trades under RMTI ticker. |
| When did Rockwell Medical go public? | Rockwell Medical went public in 1998. |
| Who are competitors of Rockwell Medical? | Similar companies to Rockwell Medical include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Rockwell Medical? | Rockwell Medical's current market cap is $33.5M |
| What is the current revenue of Rockwell Medical? | Rockwell Medical's last 12 months revenue is $87.7M. |
| What is the current revenue growth of Rockwell Medical? | Rockwell Medical revenue growth (NTM/LTM) is -19%. |
| What is the current EV/Revenue multiple of Rockwell Medical? | Current revenue multiple of Rockwell Medical is 0.3x. |
| Is Rockwell Medical profitable? | Yes, Rockwell Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Rockwell Medical? | Rockwell Medical's last 12 months EBITDA is $1.9M. |
| What is Rockwell Medical's EBITDA margin? | Rockwell Medical's last 12 months EBITDA margin is 2%. |
| What is the current EV/EBITDA multiple of Rockwell Medical? | Current EBITDA multiple of Rockwell Medical is 15.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
